ES2531368T3 - Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno - Google Patents

Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno Download PDF

Info

Publication number
ES2531368T3
ES2531368T3 ES02741997T ES02741997T ES2531368T3 ES 2531368 T3 ES2531368 T3 ES 2531368T3 ES 02741997 T ES02741997 T ES 02741997T ES 02741997 T ES02741997 T ES 02741997T ES 2531368 T3 ES2531368 T3 ES 2531368T3
Authority
ES
Spain
Prior art keywords
tumorigenicity
cells
diagnose
kits
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02741997T
Other languages
English (en)
Inventor
Ginette Serrero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
A&G Pharmaceutical Inc
Original Assignee
A&G Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A&G Pharmaceutical Inc filed Critical A&G Pharmaceutical Inc
Application granted granted Critical
Publication of ES2531368T3 publication Critical patent/ES2531368T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement Of Resistance Or Impedance (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)

Abstract

Un método para diagnosticar la tumorigenicidad del cáncer de mama en un paciente humano, que comprende: i. detectar GP88 en células de una muestra biológica obtenida de un paciente; ii. determinar el número de células positivas para GP88 en dicha muestra; y iii. determinar la proporción de células positivas para GP88 respecto al número total de células en dicha muestra biológica, en el que dicha proporción es indicativa de la tumorigenicidad del cáncer de mama, y en el que la muestra biológica que contiene las células de dicho paciente es una muestra de tejido de mama; GP88 en dichas células de dicho tejido de mama se detecta por inmunotinción con anticuerpo anti-GP88 humano; el número de células positivas para GP88 en dicha muestra se determina por examen microscópico; y una proporción de al menos 10% de células positivas para GP88 respecto al número total de células en dicho tejido de mama indica la tumorigenicidad del cáncer de mama.
ES02741997T 2001-06-15 2002-06-14 Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno Expired - Lifetime ES2531368T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/880,842 US6881548B2 (en) 1997-05-23 2001-06-15 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
PCT/US2002/018549 WO2002102229A2 (en) 2001-06-15 2002-06-14 Diagnosing tumorigenicity and determining resistance to anticancer therapy

Publications (1)

Publication Number Publication Date
ES2531368T3 true ES2531368T3 (es) 2015-03-13

Family

ID=25377233

Family Applications (2)

Application Number Title Priority Date Filing Date
ES02741997T Expired - Lifetime ES2531368T3 (es) 2001-06-15 2002-06-14 Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno
ES02739838T Expired - Lifetime ES2359494T3 (es) 2001-06-15 2002-06-14 Procedimientos y composiciones para inhibir, prevenir o reducir el crecimiento celular tumoral en los pacientes resistentes a los efectos antineoplásicos de la trerapia antiestrogénica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES02739838T Expired - Lifetime ES2359494T3 (es) 2001-06-15 2002-06-14 Procedimientos y composiciones para inhibir, prevenir o reducir el crecimiento celular tumoral en los pacientes resistentes a los efectos antineoplásicos de la trerapia antiestrogénica.

Country Status (12)

Country Link
US (1) US6881548B2 (es)
EP (2) EP1404365B1 (es)
JP (5) JP4392238B2 (es)
KR (3) KR100972053B1 (es)
CN (2) CN101584862B (es)
AT (1) ATE496635T1 (es)
AU (2) AU2002315060B2 (es)
CA (2) CA2450666A1 (es)
DE (1) DE60239059D1 (es)
ES (2) ES2531368T3 (es)
HK (1) HK1083366A1 (es)
WO (2) WO2002102306A2 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091047B2 (en) * 1997-05-23 2006-08-15 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US8512960B2 (en) * 1997-05-23 2013-08-20 A&G Pharmaceutical, Inc. 88kDa tumorigenic growth factor and antagonists
US6309826B1 (en) 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US20030219818A1 (en) * 2002-05-10 2003-11-27 Bohen Sean P. Methods and compositions for determining neoplastic disease responsiveness to antibody therapy
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
ES2369695T3 (es) * 2003-02-26 2011-12-05 A & G PHARMACEUTICAL, INC. Métodos para incrementar la proliferación de células b.
KR20060070491A (ko) * 2003-06-23 2006-06-23 에이 앤드 지 파마슈티컬즈, 인코포레이티드 항종양 요법에 대한 종양 세포의 감수성 회복 및 세포 사멸유도를 위한 조성물 및 방법
EP1849480A3 (en) * 2003-06-23 2013-06-26 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity of tumor cells to antitumor therapy and inducing apoptosis
WO2005011590A2 (en) * 2003-08-01 2005-02-10 A & G Pharmaceutical, Inc. Compositions and methods for restoring sensitivity to treatment with her2 antagonists
JP5336479B2 (ja) 2007-06-13 2013-11-06 スリーエム イノベイティブ プロパティズ カンパニー 固定可能なマウント材料及びその製造方法並びに使用方法
US20090269773A1 (en) * 2008-04-29 2009-10-29 Nodality, Inc. A Delaware Corporation Methods of determining the health status of an individual
WO2010028373A2 (en) * 2008-09-05 2010-03-11 A&G Pharmaceutical, Inc. Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
WO2013164823A1 (en) * 2012-05-03 2013-11-07 Medial Research Ltd. Methods and systems of evaluating a risk of a gastrointestinal cancer
JP6148540B2 (ja) * 2013-06-07 2017-06-14 株式会社島津製作所 質量分析装置を用いたグラニュリンペプチドの定量分析方法、および分析用プログラム
CN108024959A (zh) * 2015-07-14 2018-05-11 阿托萨遗传学公司 用于治疗乳腺病症的经***方法和组合物
JP2020533283A (ja) 2017-09-11 2020-11-19 アトッサ セラピューティクス，インク． エンドキシフェンを製造および使用する方法
EP3821032A1 (en) * 2018-07-13 2021-05-19 HiFiBiO SAS Use of droplet single cell epigenome profiling for patient stratification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416192A (en) 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
CA2023030A1 (en) * 1990-07-13 1992-01-14 Robert R. Guerrero In vitro method and probe for detecting the presence of the ring shaped particle and malignancy in humans and animals
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
US6309826B1 (en) * 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
ATE278421T1 (de) * 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms

Also Published As

Publication number Publication date
HK1083366A1 (en) 2006-06-30
WO2002102229A9 (en) 2008-07-10
AU2002312462B2 (en) 2007-08-30
EP1399739B1 (en) 2014-11-26
KR100972053B1 (ko) 2010-07-23
WO2002102229A3 (en) 2003-10-30
JP4392238B2 (ja) 2009-12-24
JP2009215302A (ja) 2009-09-24
JP2005524602A (ja) 2005-08-18
US20020025543A1 (en) 2002-02-28
JP2013139473A (ja) 2013-07-18
KR100980105B1 (ko) 2010-09-07
US6881548B2 (en) 2005-04-19
ATE496635T1 (de) 2011-02-15
JP4348178B2 (ja) 2009-10-21
EP1404365B1 (en) 2011-01-26
CN101584862A (zh) 2009-11-25
CN101584862B (zh) 2016-04-06
EP1399739A4 (en) 2006-07-19
KR101258254B1 (ko) 2013-04-25
WO2002102306A2 (en) 2002-12-27
KR20090045423A (ko) 2009-05-07
KR20100050580A (ko) 2010-05-13
DE60239059D1 (de) 2011-03-10
EP1399739A2 (en) 2004-03-24
AU2002315060B2 (en) 2007-07-12
CN100397081C (zh) 2008-06-25
WO2002102229A2 (en) 2002-12-27
CN1682111A (zh) 2005-10-12
EP1404365A4 (en) 2006-04-12
JP2015227369A (ja) 2015-12-17
JP2005514907A (ja) 2005-05-26
CA2450666A1 (en) 2002-12-27
WO2002102306A8 (en) 2004-05-21
CA2450590A1 (en) 2002-12-27
KR20040043128A (ko) 2004-05-22
EP1404365A2 (en) 2004-04-07
WO2002102306A3 (en) 2003-06-05
ES2359494T3 (es) 2011-05-24

Similar Documents

Publication Publication Date Title
ES2531368T3 (es) Métodos y kits para diagnosticar tumorigenicidad y determinar resistencia a los efectos antineoplásicos de la terapia antiestrógeno
AR107561A2 (es) Ensayo elisa para la detección de vegf
Russell et al. Polyamines as predictors of success and failure in cancer chemotherapy
Lee et al. Highly selective two-photon imaging of cysteine in cancerous cells and tissues
CY1115080T1 (el) Μεθοδοι και kit για να διαγνωσκεται ανεπαρκεια αυξητικης ορμονης
BRPI0512256A (pt) método para caracterizar o estágio de desenvolvimento ou patologia de uma amostra de tecido; método de identificação de uma célula de interesse ou de sincìcios multe-nuclear de interesse; método para diagnóstico de pré-neoplasia ou neoplasia; métodos de identificação de um ou mais agentes anti-tumorìgenos e método de preparação de uma amostra de tecido de mamìfero adequada para a identificação de células
DE602005017519D1 (de) Automatische glykofingerabdruck-strategie
MX2007005053A (es) Metodo para evaluar la enfermedad de alzheimer y reactivo de diagnostico.
HK1090093A1 (en) Method of selecting patients suitable for wt1 vaccine
Yan et al. NAG-targeting fluorescence based probe for precision diagnosis of kidney injury
BR112012007561A2 (pt) padrões de desenvolvimento de fibroblasto para diagnóstico de doença de alzheimer
ES2194116T3 (es) Procedimiento para detectar anticuerpos antipolimero y kit de prueba de diagnostico para uso como ayuda al diagnostico de las enfermedades relacionadas con silicona.
RU2010101909A (ru) Способ выявления или лечения реакции "трансплантат против хозяина"
EP1600513A4 (en) METHOD FOR STUDYING A CELL
ES2570609T3 (es) Método para someter a ensayo la aminoacilasa 1 para el diagnóstico in vitro del cáncer colorrectal
BRPI0315735B8 (pt) método para o ensaio de ngf a diagnose in vitro de câncer de mama e uso terapêutico
Hu et al. Detection of hypoxic fractions in murine tumors by comet assay: comparison with other techniques
CN103344768B (zh) 缺血性心脏病检测试剂盒及其应用
BRPI0610267B8 (pt) métodos de detecção de um estado doentio ou de uma suscetibilidade à doença em um indivíduo mamífero, e, uso do método
BR0209681A (pt) Método e kit para o diagnóstico in vivo ou para o monitoramento de uma doença que envolve uma reação inflamatória dentro de um paciente
NI201000037A (es) Análisis de enfermedades infecciosas en fluido menstrual, células endometriales/menstruales, fluido amniótico, sangre de cordón umbilical u otras muestras.
KR100784469B1 (ko) Ｕｖ광 흡수스펙트럼을 이용한 세포의 정상세포, 암세포진단장치 및 방법
ATE466285T1 (de) Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers
RU2697722C1 (ru) Способ диагностики активности воспалительного процесса при латентном течении хронического пиелонефрита
KR20150097892A (ko) 크레아티닌 보정을 통한 인체 내 활성산소 검출수단 및 그 방법